True Vision MN LLC Buys Shares of 4,464 Gilead Sciences, Inc. $GILD

True Vision MN LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,464 shares of the biopharmaceutical company’s stock, valued at approximately $622,000.

Several other hedge funds and other institutional investors have also made changes to their positions in GILD. Paulson Wealth Management Inc. increased its holdings in Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares during the last quarter. Essex Financial Services Inc. lifted its stake in Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after buying an additional 71 shares during the period. Alpha Cubed Investments LLC boosted its holdings in Gilead Sciences by 1.1% during the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after buying an additional 75 shares during the last quarter. Personal CFO Solutions LLC grew its position in shares of Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 76 shares during the period. Finally, Moss Adams Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after acquiring an additional 76 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

Shares of GILD opened at $123.76 on Monday. The firm has a market cap of $153.66 billion, a P/E ratio of 16.86 and a beta of 0.31. Gilead Sciences, Inc. has a twelve month low of $104.46 and a twelve month high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The firm’s 50 day moving average price is $131.66 and its two-hundred day moving average price is $134.28.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the firm earned $1.81 earnings per share. The firm’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the transaction, the chief executive officer directly owned 617,567 shares in the company, valued at approximately $81,185,357.82. This trade represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 68,000 shares of company stock worth $8,930,150. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of a number of analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research report on Monday, February 23rd. Jefferies Financial Group began coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price for the company. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a report on Wednesday, May 20th. Truist Financial reissued a “buy” rating and set a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Finally, Morgan Stanley decreased their price target on shares of Gilead Sciences from $175.00 to $168.00 in a report on Friday, May 8th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $158.41.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.